Obesity Pipeline Analysis, 2025 by DelveInsight | Zealand Pharma, Sciwind Biosciences, Genexine, Sirnaomics, Sparrow Pharmaceuticals, Shionogi, Regor Pharmaceuticals, Innovent Biologics, Pfizer, NodTh

DelveInsight's, "Obesity - Pipeline Insight, 2025" report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Obesity pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
According to DelveInsight, over 80 companies are actively developing more than 100 therapies for Obesity.

Obesity Overview:

Obesity is the excessive accumulation of body fat that adversely affects health and raises the risk of conditions such as type 2 diabetes, cardiovascular disease, hypertension, and high cholesterol. It has emerged as a major public health concern, with prevalence increasing steadily over the past five decades.

This complex, multifactorial condition is a leading cause of preventable death after smoking. Research indicates that even a modest weight loss of 5-10% can significantly improve health outcomes, quality of life, and reduce healthcare costs for individuals and society.

Obesity primarily results from an imbalance between energy intake and expenditure, though it is also influenced by genetic predisposition, cultural norms, and social environments. Studies show obesity is highly heritable, with multiple genes associated with increased body fat and weight gain.

Other contributing factors include sedentary lifestyles, sleep disruptions, hormonal disorders, certain medications, widespread consumption of high-calorie, high-sugar foods, and reduced metabolic efficiency.

Download our report @ https://www.delveinsight.com/report-store/obesity-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

"Obesity Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Obesity Therapeutics Market.

Key Takeaways from the Obesity Pipeline Report

*
DelveInsight's Obesity pipeline report highlights a dynamic landscape, with over 80 companies developing more than 100 therapies for obesity.

*
In March 2024, the FDA approved Wegovy for an additional indication: reducing the risk of major cardiovascular events-including heart attack, stroke, and cardiovascular death-in adults with known heart disease who are overweight or have obesity, emphasizing benefits beyond weight management.

*
Key players advancing obesity treatments include Zealand Pharma, Sciwind Biosciences, Genexine, Sirnaomics, Sparrow Pharmaceuticals, Shionogi, Regor Pharmaceuticals, Innovent Biologics, Pfizer, NodThera, Boehringer Ingelheim, Fractyl Health, TransThera, Clearmind Medicine, PegBio, Biolingus, and others. Promising pipeline candidates in various development stages include Survodutide, Ecnoglutide, CT-868, DD01, among others.

Obesity Pipeline Analysis

The Obesity pipeline insights report 2025, provides insights into:

*
Provides comprehensive insights into key companies developing therapies in the Obesity Market.

*
Categorizes Obesity therapeutic companies by development stage: early, mid, and late-stage.

*
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.

*
Reviews emerging Obesity drugs under development based on:

*
Stage of development

*
Obesity Route of administration

*
Target receptor

*
Monotherapy vs. combination therapy

*
Obesity Mechanism of action

*
Molecular type

*
Offers detailed analysis of:

*
Company-to-company and company-academia collaborations

*
Obesity Licensing agreements

*
Funding and investment activities supporting future Obesity market advancement.

Request for a sample report @ https://www.delveinsight.com/sample-request/obesity-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Obesity Emerging Drugs

*
Survodutide: Zealand Pharma

*
Ecnoglutide: Sciwind Biosciences

*
CT-868: Carmot Therapeutics

*
DD01: D&D Pharmatech

Obesity Companies

Over 80 leading companies are actively developing therapies for obesity, with Zealand Pharma among those advancing a candidate to the Phase III stage, the most advanced phase of clinical development.

DelveInsight's report covers around 100+ products under different phases of Obesity clinical trials like

*
Obesity Late stage Therapies (Phase III)

*
Obesity Mid-stage Therapies (Phase II)

*
Obesity Early-stage Therapies (Phase I)

*
Obesity Pre-clinical and Obesity Discovery stage Therapies

*
Obesity Discontinued & Inactive Therapies

Obesity pipeline report provides the Obesity therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

*
Intravenous

*
Subcutaneous

*
Oral

*
Intramuscular

Obesity Products have been categorized under various Molecule types such as

*
Monoclonal antibody

*
Small molecule

*
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Obesity Therapies and Key Obesity Companies: Obesity Clinical Trials and recent advancements [https://www.delveinsight.com/report-store/obesity-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Obesity Pipeline Therapeutic Assessment

- Obesity Assessment by Product Type

- Obesity By Stage

- Obesity Assessment by Route of Administration

- Obesity Assessment by Molecule Type

Download Obesity Sample report to know in detail about the Obesity treatment market @ Obesity Therapeutic Assessment [https://www.delveinsight.com/sample-request/obesity-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Table of Content

1. Report Introduction

2. Executive Summary

3. Obesity Current Treatment Patterns

4. Obesity - DelveInsight's Analytical Perspective

5. Therapeutic Assessment

6. Obesity Late-Stage Products (Phase-III)

7. Obesity Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Obesity Discontinued Products

13. Obesity Product Profiles

14. Obesity Key Companies

15. Obesity Key Products

16. Dormant and Discontinued Products

17. Obesity Unmet Needs

18. Obesity Future Perspectives

19. Obesity Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Obesity Pipeline Reports Offerings [https://www.delveinsight.com/report-store/obesity-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=obesity-pipeline-analysis-2025-by-delveinsight-zealand-pharma-sciwind-biosciences-genexine-sirnaomics-sparrow-pharmaceuticals-shionogi-regor-pharmaceuticals-innovent-biologics-pfizer-nodth]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.